Back to top
more

Disc Medicine, Inc. (IRON)

(Real Time Quote from BATS)

$58.04 USD

58.04
135,984

+0.01 (0.02%)

Updated Aug 11, 2025 01:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy

by Zacks Equity Research

Disc Medicine, Inc. (IRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Wall Street Analysts Predict a 68.78% Upside in Disc Medicine, Inc. (IRON): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 68.8% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Disc Medicine, Inc. (IRON) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Disc Medicine, Inc. (IRON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks Equity Research

Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More

by Zacks Equity Research

Disc Medicine, Inc. (IRON) and Verve Therapeutics (VERV) fall on study updates.

Zacks Equity Research

Disc Medicine (IRON) Down on Mixed Results From AURORA Study

by Zacks Equity Research

Disc Medicine's (IRON) shares lose after a phase II study of bitopertin in patients with erythropoietic protoporphyria does not achieve the key secondary endpoint.

Zacks Equity Research

How Much Upside is Left in Disc Medicine, Inc. (IRON)? Wall Street Analysts Think 38.17%

by Zacks Equity Research

The mean of analysts' price targets for Disc Medicine, Inc. (IRON) points to a 38.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Recent Price Trend in Disc Medicine, Inc. (IRON) is Your Friend, Here's Why

by Zacks Equity Research

Disc Medicine, Inc. (IRON) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

Here's Why Disc Medicine, Inc. (IRON) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Disc Medicine, Inc. (IRON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks Equity Research

Is a Surprise Coming for Disc Medicine (IRON) This Earnings Season?

by Zacks Equity Research

Disc Medicine (IRON) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Disc Medicine, Inc. (IRON) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Disc Medicine, Inc. (IRON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

Disc Medicine, Inc. (IRON) Is Up 4.40% in One Week: What You Should Know

by Zacks Equity Research

Does Disc Medicine, Inc. (IRON) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Zacks.com featured highlights Harrow Health and Disc Medicine Opco

by Zacks Equity Research

Harrow Health and Disc Medicine Opco have been highlighted in this Screen of The Week article.

Shrabana Mukherjee headshot

2 Stocks in Focus as Analysts Initiate Coverage

by Shrabana Mukherjee

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Harrow Health (HROW) and Disc Medicine (IRON).

Zacks Equity Research

Recent Price Trend in Disc Medicine, Inc. (IRON) is Your Friend, Here's Why

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Disc Medicine, Inc. (IRON) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Shrabana Mukherjee headshot

3 Stocks in the Limelight on New Analyst Coverage

by Shrabana Mukherjee

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Disc Medicine (IRON), Westamerica (WABC) and Enliven (ELVN).